1st Quarter Results - Part 2

AstraZeneca PLC
25 April 2002


PART 2

Consolidated Profit & Loss Account




                                                                                    1st Quarter       1st Quarter
                                                                                           2002           2001
                                                                                                       (restated)
                                                                                             $m               $m

Sales                                                                                    4,421             3,991
Cost of sales                                                                           (1,169)           (1,074)
Distribution costs                                                                         (30)              (30)
Research and development                                                                  (697)             (672)
Selling, general and administrative expenses                                            (1,384)           (1,321)
Other operating income                                                                     156               161
Operating profit before exceptional items                                                1,297             1,055

Exceptional items charged to operating profit                                                -               (25)
Operating profit                                                                         1,297             1,030
Profit on sale of fixed assets                                                               -                10
Net interest and dividend income                                                            21                55
Profit on ordinary activities before taxation                                            1,318             1,095

Taxation                                                                                  (356)             (309)
Profit on ordinary activities after taxation                                               962                786

Attributable to minorities                                                                  (4)               (3)
Net profit for the period                                                                  958               783


Earnings per Ordinary Share before exceptional items                                     $0.55             $0.45
Earnings per Ordinary Share                                                              $0.55             $0.44
Diluted earnings per Ordinary Share                                                      $0.55             $0.44
Weighted average number of Ordinary Shares in issue (millions)                           1,745             1,766
Diluted average number of Ordinary Shares in issue (millions)                            1,747             1,768


Consolidated Balance Sheet


                                                                                       31 March         31 March
                                                                                            2002             2001
                                                                                                        (restated)
                                                                                              $m               $m

Fixed assets                                                                             8,205             7,650

Current assets                                                                          11,754            11,484
Total assets                                                                            19,959            19,134

Creditors due within one year                                                           (7,220)           (6,994)
Net current assets                                                                       4,534             4,490

Total assets less current liabilities                                                   12,739            12,140

Creditors due after more than one year                                                    (788)             (903)
Provisions for liabilities and charges                                                  (1,473)           (1,678)
Net assets                                                                              10,478             9,559

Capital and reserves

Shareholders' funds and minority interests                                              10,478             9,559







Consolidated Cash Flow Statement


                                                                                     1st Quarter       1st Quarter
                                                                                            2002              2001
                                                                                              $m                $m
Cash flow from operating activities

Operating profit before exceptional items                                                 1,297             1,055
Depreciation and amortisation                                                               227               212
Decrease in working capital and other non-cash movements                                    409               110
Net cash inflow from operating activities before exceptional items                        1,933             1,377

Outflow related to exceptional items                                                        (28)             (105)
Net cash inflow from operating activities                                                 1,905             1,272

Returns on investments and servicing of finance                                              (6)               58

Tax paid                                                                                    (54)              (86)

Capital expenditure and financial investment                                               (285)             (345)

Acquisitions and disposals                                                                    -               (20)

Net cash inflow before management of liquid resources
  and financing                                                                           1,560               879
Net purchase of shares                                                                     (133)             (126)
Exchange and other movements                                                                 (2)              (42)
Increase in net cash funds in the period                                                   1,425              711

Net cash funds at beginning of period                                                      2,867            3,605

Net cash funds at end of period                                                            4,292            4,316




Notes to the Interim Financial Statements



1                BASIS OF PREPARATION AND ACCOUNTING POLICIES

The results for the quarter ended 31 March 2002 have been prepared in accordance
with UK generally accepted accounting principles.  The accounting policies
applied are those set out in AstraZeneca PLC's 2001 Annual Report and Form 20-F
except that, in the current period, AstraZeneca adopted Financial Reporting
Standard No. 19 'Deferred Tax'.  Prior periods have been restated and the
effects of this restatement were to increase profits for the quarter ended 31
March 2001 by $1m and reduce net assets at that date by $106m.  On adoption net
assets at 1 January 2002 were reduced by $193m.  The table below illustrates the
effect on EPS before exceptional items of this restatement.

These interim financial statements do not constitute statutory accounts within
the meaning of Section 240 of the Companies Act 1985.  Statutory accounts for
the year ended 31 December 2001 will be filed with the Registrar of Companies
following the Company's Annual General Meeting.  The auditor's report on those
accounts was unqualified and did not contain any statement under Section 237 of
the Companies Act 1985.



2001 TAXATION AND EARNINGS PER SHARE BEFORE EXCEPTIONAL ITEMS

                                                 Q1 2001      Q2 2001      Q3 2001      Q4 2001           Year

Tax charge before adoption of FRS 19 ($m)          (316)        (269)        (286)        (282)        (1,153)
Tax charge  after adoption of FRS 19 ($m)          (315)        (289)        (295)        (315)        (1,214)
Published EPS before adoption of FRS 19 ($)        0.45    .    0.42         0.43         0.47           1.77

Adjusted EPS after adoption of FRS 19 ($)          0.45         0.41         0.42         0.45           1.73



2   TERRITORIAL SALES ANALYSIS

                                                                                          % Growth
                                                        1st              1st
                                                     Quarter          Quarter
                                                       2002             2001                        Constant
                                                         $m               $m          Actual        Currency


       USA                                            2,448            2,139             14               14
       Japan                                            172              178             (3)              10
       France                                           265              238             11               13
       Germany                                          167              168             (1)               1
       Italy                                            172              150             15               18
       Sweden                                            64               67             (4)               6
       UK                                               180              172              5                7
       Rest of World                                    953              879              8               11
Total                                                 4,421            3,991             11               13




3     PRODUCT SALES ANALYSIS


                                                         World                                           US
                                          1st          1st                  Constant           1st
                                      Quarter      Quarter                                 Quarter
                                         2002         2001       Actual     Currency          2002        Actual
                                                                 Growth       Growth                      Growth
                                           $m           $m            %            %           $m              %
                                                                                               
Gastrointestinal:
Losec                                   1,218        1,495         (19)         (18)           744        (26)
Nexium                                    356           81         n/m           n/m           293         n/m
Others                                     13           12           8            8              4          -
Total Gastrointestinal                  1,587        1,588           -            1          1,041         (2)

Cardiovascular:
Zestril                                   283          294          (4)          (3)           183          1
Seloken                                   236          151          56           57            166        100
Plendil                                   108          106           2            4             45          7
Tenormin                                   94           98          (4)           -             22         69
Atacand                                   151           83          82           84             73        170
Others                                     89          103         (14)         (11)             6        (63)
Total Cardiovascular                      961          835          15           17            495         36

Respiratory:
Pulmicort                                 229          200          15           17            107         70
Rhinocort                                  64           56          14           14             44         29
Accolate                                   33           49         (33)         (31)            23        (36)
Oxis                                       31           32          (3)          (3)             -          -
Symbicort                                  54            3          n/m          n/m             -          -
Others                                     35           41         (15)         (10)             -          -
Total Respiratory                         446          381          17           19            174         31

Oncology:
Zoladex                                   190          160          19           23             48         (2)
Nolvadex                                  143          139           3            5            111          6
Casodex                                   124          115           8           12             31        (37)
Arimidex                                   66           43          53           55             27         69
Others                                      5            7         (29)         (29)             -          -
Total Oncology                            528          464          14           17            217         (1)

CNS:
Seroquel                                  336          189          78           79            293         80
Zomig                                      93           66          41           43             60         50
Others                                      7            2         n/m          n/m              2          -
Total CNS                                 436          257          70           71            355         73
Pain, Infection and Other

Pharma:
Diprivan                                  113          107           6            9             55         28
Merrem                                     67           49          37           39             15         67
Local anaesthetics                         96          104          (8)          (4)            22        (15)
Other Pharma Products                      71          104         (32)         (28)            18        (36)
Total Pain, Infection and Other
  Pharma
                                          347          364                       (2)           110          4
                                                                    (5)
Salick Health Care                         54           45          20           20             54         20
Astra Tech                                 34           30          13           23              2          -
Marlow Foods                               28           27           4            4              -          -

Total                                   4,421        3,991          11           13          2,448         14



n/m   not meaningful


Shareholder Information



ANNOUNCEMENTS AND MEETINGS




Annual General Meeting                                             25 April 2002
Announcement of half year results                                   25 July 2002
Announcement of third quarter and nine month results             24 October 2002
Annual Business Review                                           7 November 2002





DIVIDENDS




The record date for the second interim dividend payable on 8 April 2002 (in the
UK, Sweden and the US) was 22 February 2002.  Ordinary Shares traded ex-dividend
on the London and Stockholm Stock Exchange from 20 February 2002.  ADRs traded
ex-dividend on the New York Stock Exchange from the same date.



Future dividends will normally be paid as follows:

First Interim                         Announced end of July and paid in October.
Second nterim                         Announced in January and paid in April.

                                                          

TRADEMARKS



The following brand names used in this interim report are trade marks of the
AstraZeneca group of companies:


Accolate  Arimidex  Astra Tech  Atacand  Atacand HCT  Atacand Plus  Casodex
Crestor  Diprivan  Exanta  Faslodex  Iressa  Losec   Merrem   Nexium  Nolvadex
Oxis  Plendil  Prilosec Pulmicort  Pulmicort Respules  Pulmicort Turbuhaler
Rhinocort  Rhinocort Aqua  Seloken  Seroquel  Symbicort  Tenormin  Toprol-XL
Zestril  Zoladex  Zomig  Zomig Rapimelt



ADDRESSES FOR CORRESPONDENCE




Registrar and Transfer       Depositary for ADRs      Registered Office     Swedish Securities Register
Office                                                                      Centre
The AstraZeneca Registrar    JPMorgan Chase Bank      15 Stanhope Gate      VPC AB
Lloyds TSB Registrars        ADR Service Center       London                PO Box 7822
The Causeway                 PO Box 842006            W1K 1LN               S-103 97 Stockholm
Worthing                     Boston, MA 02284-2006                          Sweden
West Sussex
BN99 6DA
Tel: [phone]         Tel: [phone]      Tel: [phone]  Tel: [phone]



CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS





In order to utilise the 'Safe Harbor' provisions of the United States Private
Securities Litigation Reform Act of 1995, AstraZeneca is providing the following
cautionary statement.  This Interim Report contains forward-looking statements
with respect to the financial condition, results of operations and businesses of
AstraZeneca.  By their nature, forward-looking statements and forecasts involve
risk and uncertainty because they relate to events and depend on circumstances
that will occur in the future.  There are a number of factors that could cause
actual results and developments to differ materially from that expressed or
implied by these forward-looking statements.  These factors include, among other
things, exchange rate fluctuations, the risk that research and development will
not yield new products that achieve commercial success, the impact of
competition, price controls and price reductions, the risk of loss or expiration
of patents or trade marks, difficulties of obtaining and maintaining
governmental approvals for products, the risk of substantial product liability
claims, exposure to environmental liability.



                      This information is provided by RNS
            The company news service from the London Stock Exchange